Phase II Trial of Arsenic Trioxide and Thalidomide in the Treatment of Patients With Refractory Multiple Myeloma

II

To determine the effectiveness of arsenic trioxide in combination with thalidomide

• Diagnosis of multiple myeloma
• relapsed from or are refractory to up to 3 prior therapies
• previous thalidomide therapy is appropriate but not necessary
• adequate liver and kidney function
• limited neuropathy

Patients receive Trisenox® by IV injection over 1 hour Monday through Friday during week 1, and then twice weekly during weeks 2 through 4. On weeks 5 and 6, patients do not receive Trisenox. Patients receive oral thalidomide daily starting the first day of treatment (1 cycle = 6 weeks). Depending on patients responses, they may stay on treatment for up to 8 cycles

Tennessee
Craig Henderson, MD
901-684-1900